Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. Read more about Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. Read more about Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis. Read more about The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis.
Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. Read more about Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Read more about Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas.
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis. Read more about Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis.
PARP inhibitors for prostate cancer: for whom and when? Read more about PARP inhibitors for prostate cancer: for whom and when?
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis. Read more about New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis.
Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis. Read more about Cancer incidence and mortality estimates in 2022 in southeast Asia: a comparative analysis.
FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply. Read more about FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply.
